@article{3683b0743f9c43af9c28eb7847061237,
title = "Regulation of In Situ to Invasive Breast Carcinoma Transition",
abstract = "The transition of ductal carcinoma in situ (DCIS) to invasive carcinoma is a poorly understood key event in breast tumor progression. Here, we analyzed the role of myoepithelial cells and fibroblasts in the progression of in situ carcinomas using a model of human DCIS and primary breast tumors. Progression to invasion was promoted by fibroblasts and inhibited by normal myoepithelial cells. Molecular profiles of isolated luminal epithelial and myoepithelial cells identified an intricate interaction network involving TGFβ, Hedgehog, cell adhesion, and p63 required for myoepithelial cell differentiation, the elimination of which resulted in loss of myoepithelial cells and progression to invasion.",
keywords = "CELLBIO, CELLCYCLE",
author = "Min Hu and Jun Yao and Carroll, {Danielle K.} and Stanislawa Weremowicz and Haiyan Chen and Daniel Carrasco and Andrea Richardson and Shelia Violette and Tatiana Nikolskaya and Yuri Nikolsky and Bauerlein, {Erica L.} and Hahn, {William C.} and Gelman, {Rebecca S.} and Craig Allred and Bissell, {Mina J.} and Stuart Schnitt and Kornelia Polyak",
note = "Funding Information: We greatly appreciate the help of Diana Calogrias with the acquisition of human tissue samples and Natasha Pliss with immunohistochemistry. We thank Drs. John Mountz (University of Alabama, Birmingham, AL), Steven Goldring (Hospital for Special Surgery, New York, NY), Ole Petersen (Panem Institute, Denmark), Jerry Shay (University of Texas Southwestern Medical Center, Dallas, TX) for providing us with cells as described above; Dr. Paul Weinreb (Biogen-Idec, Cambridge, MA) for help with ITGB6 assays; Dr. Jonathan Yingling (Eli Lilly, Indianapolis, IN) for TGFBR inhibitors; Dr. Tae-Hwa Chun (University of Michigan, Ann Arbor, MI) for retroviral constructs encoding MMP14, the Broad Institute TRC for shRNA constructs; Dr. Bert Vogelstein, Dr. Myles Brown, and Lauren Campbell for their critical reading of the manuscript; and the Genome Sciences Centre, British Columbia Cancer Agency, Vancouver Canada for sequencing. This work was supported in part by NIH (CA89393, CA94074, and CA116235), DOD (W8IXWH-04-1-0452), and ACS (RSG-05-154-01-MGO) grants to KP; DOD (W81XWH-07-1-0408) to W.C.H.; Susan G. Komen Foundation fellowship (PDF042234) to M.H.; and by Biogen-Idec. Work from the M.J.B. laboratory was supported by NIH (CA64786) to M.J.B. and Ole Petersen. K.P. and W.C.H. receive research support from and are consultants to Novartis Pharmaceuticals, Inc. K.P. also receives research support from Biogen-Idec and is a consultant to Aveo Pharmaceuticals, Inc. ",
year = "2008",
month = may,
day = "6",
doi = "10.1016/j.ccr.2008.03.007",
language = "English (US)",
volume = "13",
pages = "394--406",
journal = "Cancer cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "5",
}